SCHEMBL2229126

SCHEMBL2229126

CCCCCCCc1[nH]cc[n+]1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.40
GPR84 Q9NQS5 1/20 0.40
ADRA2A P08913 3/20 0.35
ADORA3 P0DMS8 3/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
CHRM2 P08172 2/20 0.35
CHRM1 P11229 2/20 0.35
ACHE P22303 2/20 0.35
ESR1 P03372 2/20 0.35
ABCB11 O95342 1/20 0.35
PGR P06401 1/20 0.35
HTR1A P08908 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
PTGS1 P23219 1/20 0.35
PDE4A P27815 1/20 0.35
ADRA1A P35348 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627668 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL2403678 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL233861 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL1299806 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL4347828 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL3885723 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL2351436 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL1818170 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL5300868 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2
SCHEMBL3664070 1.00 KCNH2 (0.40) KCNH2GPR84ADRA2AADORA3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250196021-A1 METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS CHEVRON PHILLIPS CHEMICAL COMPANY LP 2025-06-19 US claimed
WO-2025128828-A1 METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2025-06-19 WO claimed
CN-107427758-B Separation using ionic liquid solvents 切弗朗菲利浦化学公司 2020-11-20 CN claimed
WO-2019143802-A1 DISSOLUTION OF CELLULOSE IN IONIC LIQUIDS TEXAS TECH UNIVERSITY SYSTEM (US) 2019-07-25 WO claimed
US-10227274-B2 Separations with ionic liquid solvents CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2019-03-12 US claimed
EP-3244987-A1 SEPARATIONS WITH IONIC LIQUID SOLVENTS Chevron Phillips Chemical Company LP (US) 2017-11-22 EP claimed
US-20150133711-A1 Separations With Ionic Liquid Solvents CHEVRON PHILLIPS CHEMICAL COMPANY LP 2015-05-14 US claimed
WO-2010125302-A1 USE OF IONIC LIQUID FOR THE PERMANENT SHAPING OF KERATINIC FIBRES L'OREAL (FR) 2010-11-04 WO claimed
EP-2027225-A2 VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-02-25 EP claimed
EP-2021276-A2 PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-02-11 EP claimed
WO-2007143051-A2 VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-12-13 WO claimed
WO-2007143055-A2 PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-12-13 WO claimed
WO-2001081329-A1 METHOD FOR THE PREPARATION OF CHIRAL EPOXIDES KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2001-11-01 WO claimed
US-20260015304-A1 METAL-CONTAINING IONIC LIQUIDS WITH REDUCED VISCOSITY CHEVRON PHILLIPS CHEMICAL CO LP (US) 2026-01-15 US disclosed
US-12441671-B2 Metal-containing ionic liquids with reduced viscosity CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2025-10-14 US disclosed
US-12365647-B2 Method for preparing acrylonitrile dimer LG CHEM, LTD. (KR) 2025-07-22 US disclosed
WO-2007038363-A2 UTILIZING IONIC LIQUIDS FOR HYDROFLUOROCARBON SEPARATION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-04-05 WO disclosed
WO-2006111712-A2 IONIC LIQUIDS AND USES THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2006-10-26 WO disclosed
WO-2002012171-A1 METHOD FOR PREPARING CHIRAL COMPOUND BY ASYMMETRIC RING OPENING REACTIONS OF EPOXIDES KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2002-02-14 WO disclosed
WO-2001003211-A1 HYDROPHOBIC IONIC SALTS AND NONAQUEOUS ELECTROLYTES COVALENT ASSOCIATES, INC. (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365647-B2 Method for preparing acrylonitrile dimer ADH1C, ADH1A, PUF60 KCNH2 3203/4885GPR84 4549/4885ADRA2A 3466/4885
US-20260015304-A1 METAL-CONTAINING IONIC LIQUIDS WITH REDUCED VISCOSITY EXOC3, ELL, IGF2BP2 KCNH2 552/4885GPR84 4881/4885ADRA2A 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.